Interestingly, altered NAMPT levels have been implicated in metabolic disorders and cancer, and FK866, a highly specific NAMPT inhibitor that abolishes NAD+ circadian oscillations and thereby SIRT1 cyclic activity, is used to control cell death in human cancer tissues. This evidence concerns the gene NAMPT and metabolic disease.